<DOC>
	<DOCNO>NCT02417207</DOCNO>
	<brief_summary>The purpose study observe new scheme achieve traditional scheme effect prevent hepatitis B recurrence .</brief_summary>
	<brief_title>Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin ( HBIG ) Prevent Hepatitis B Recurrence After Liver Transplantation</brief_title>
	<detailed_description>At present , prevention hepatitis B recurrence liver transplantation commonly use scheme nucleoside analogue combine hepatitis B immune globulin ( HBIG ) . HBIG condense prevent efficient price invasion hepatitis b immunoglobulin , function direct virus.Also block virus liver cell . Lamivudine HBIG therapy hepatitis b recurrence rate reduce 10 % , entecavir combine HBIG hepatitis b recurrence rate low 1 % . In European American country , HBIG commonly use method long-term high-dose intravenous drip , country long-term low-dose intramuscular injection , need lifelong medication , long surgery patient disable HBIG consensus . Whether long-term intravenous drip intramuscular HBIG , disadvantage high cost , drug side effect , also bring inconvenience patient . The advent potent hepatitis b virus drug continuously background , recent year , scholar already begin application short-term application HBIG discontinuation prevent hepatitis b recurrence research , low transplantation hepatitis B virus ( HBV ) DNA replication , effective antiviral therapy hepatitis b recurrence transplantation create condition HBIG solution . Most study suggest transplantation nucleoside analogues alone long time without application short-term application HBIG scheme prevent hepatitis b recurrence safe , several transplant center study abroad , Chinese mainland application short-term application HBIG clinical study . Entecavir potent antiviral capacity high genetic barrier resistance , low incidence drug resistance , currently prevention treatment hepatitis b recurrence liver transplantation first-line drug , entecavir combine long-term muscle injection low-dose HBIG present country commonly use drug liver transplantation center . This study entecavir combine liver transplantation short-term application type static note HBIG prevent hepatitis b recurrence prospective , multicenter , randomize , control experimental study , equivalence . The purpose study observe new scheme achieve traditional scheme effect prevent hepatitis B recurrence .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1. correlation disease hepatitis B viral hepatitis liver transplantation recipient first time ; 2. old 18 year old , men woman limit ; 3. preoperative HbsAg positive , regardless whether preoperative HBV DNA level , regardless whether preoperative antiviral treatment , regardless whether associate primary liver cancer ; 4. donor HbsAg negative , virology negative liver condition ; 5. integrate research , good adherence . 1. overlap type viral hepatitis ; 2. correlation endstage liver disease hepatitis b ; 3. liver transplantation , joint organ transplantation ; 4. allergic hepatitis b immune globulin ; 5. primary hepatocellular carcinoma vena cava , portal vein around trunk branch , hepatic vein large vascular invasion ; 6 . ABO blood group incompatibility liver transplantation ; 7. moderately severe renal insufficiency , serum creatinine 180 umol/L high ; 8. drug resistance entecavir liver transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>hepatitis B immune globulin ( HBIG )</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>entecavir</keyword>
</DOC>